The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s ...
ABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 ...
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...
Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic ...
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust ...
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 ...
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data 55% of BriaCell patients[1] ...
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune ...
Philadelphia & Vancouver, British Columbia – October 1, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with ...
Accessibility Tools